Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.
Saved in:
| Title: | Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. |
|---|---|
| Authors: | Verstockt, Bram1,2 (AUTHOR) bram.verstockt@uzleuven.be, Pivorunas, Valerie3 (AUTHOR), Mahi, Naim Al4 (AUTHOR), Smaoui, Nizar4 (AUTHOR), Guay, Heath3 (AUTHOR), Kennedy, Nicholas A5 (AUTHOR), Goodhand, James R5 (AUTHOR), Lin, Simeng5 (AUTHOR), Bai, Benjamin Y H6 (AUTHOR), Hanauer, Stephen B7 (AUTHOR), Ferrante, Marc1,2 (AUTHOR), Panés, Julian8 (AUTHOR), Vermeire, Séverine1,2 (AUTHOR) |
| Source: | Journal of Crohn's & Colitis. Apr2024, Vol. 18 Issue 4, p493-505. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
